Related references
Note: Only part of the references are listed.Lack of association between deletion polymorphism of BIM gene and in vitro drug sensitivity in B-cell precursor acute lymphoblastic leukemia
Meixian Huang et al.
LEUKEMIA RESEARCH (2017)
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
Chadi Nabhan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy
Koichi Miyamura et al.
LEUKEMIA RESEARCH (2016)
Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: Secular trends of a population-based cancer registry from 1998 to 2012
Raymond Boon Tar Lim et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Ji Yun Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations
Hiromichi Ebi et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country
Ching-Hung Lin et al.
PLOS ONE (2015)
Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells
Duohui Jing et al.
BLOOD (2015)
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis
Shuang Chen et al.
BLOOD (2014)
The Bim Deletion Polymorphism Clinical Profile and its Relation With Tyrosine Kinase Inhibitor Resistance in Chinese Patients With Non-Small Cell Lung Cancer
Mingchuan Zhao et al.
CANCER (2014)
Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group
Yasuo Hirayama et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Clinical Significance of BIM Deletion Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
Kazutoshi Isobe et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non-Small-Cell Lung Cancer
Jih-Hsiang Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia
Sheila Xinxuan Soh et al.
PLOS ONE (2014)
Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients
Jia Zhong et al.
THORACIC CANCER (2014)
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
J. K. Lee et al.
ANNALS OF ONCOLOGY (2013)
The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients
Seiichiro Katagiri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
Takayuki Nakagawa et al.
CANCER RESEARCH (2013)
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
King Pan Ng et al.
NATURE MEDICINE (2012)
Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy
Sari Riihijarvi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Bim-Bcl-2 Homology 3 Mimetic Therapy Is Effective at Suppressing Inflammatory Arthritis Through the Activation of Myeloid Cell Apoptosis
John C. Scatizzi et al.
ARTHRITIS AND RHEUMATISM (2010)
Share Paper
